Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2015JAMA OncologyOpen Access

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDickran KazandjianSKSean KhozinGBGideon M. Blumenthal

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kazandjian et al. (2015) studied this question.

synapsesocial.com/papers/6a730722bc45bc90ae60db63https://doi.org/10.1001/jamaoncol.2015.3934
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,641 citations
  2. 2Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer2015 · 8,068 citations
  3. 3Erlotinib in Previously Treated Non–Small-Cell Lung Cancer2005 · 5,471 citations
  4. 4New modalities of cancer treatment for NSCLC: focus on immunotherapy2014 · 78 citations
  5. 5Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S14002015 · 241 citations